Myosin inhibitor research in hypertrophic cardiomyopathy accelerates from mechanism to clinical translation
Targeted treatment for hypertrophic cardiomyopathy has moved quickly from bench science into clinical debate, and the publication record now reflects that momentum. A bibliometric analysis of myosin inhibitor research captured 379 papers published between 2016 and 2025, with output rising at an exponential pace across the decade. The pattern is more than an academic curiosity. In a disease defined by hypercontractility, impaired relaxation, and dynamic obstruction in many patients, myosin inhibition targets the contractile machinery itself rather than downstream symptoms alone.
The publication curve divided naturally into three phases: mechanistic work from 2016 to 2018, clinical translation from 2019 to 2021, and personalized therapy from 2022 to 2025. Each stage tracks a familiar arc in cardiovascular therapeutics, but the speed of this one stands out. Laboratory and translational studies laid the biological foundation first, then clinical studies began to test whether reducing sarcomeric overactivity could translate into symptom relief and functional gains. By the later period, the literature broadened toward patient-specific treatment strategies, an indication that the field had moved beyond proof of concept and into refinement.
One finding was impossible to miss: the United States accounted for 37% of all publications.
Geographic concentration still shapes the evidence base
Research output clustered heavily in North America and Europe. Italy contributed 30 publications, and Germany contributed 14, but no region approached the volume generated in the United States. That concentration matters because publication leadership tends to shape trial design, funding priorities, and the pace at which new hypotheses reach patients. When a field is still forming, the geographic center of gravity often influences which questions get answered first and which remain underexplored.
At the institutional level, the University of Pennsylvania produced 39 publications and accumulated 1,585 citations, placing it among the most influential centers in this area. Bristol Myers Squibb contributed 32 publications, reflecting the central role of industry in myosin inhibitor development. The collaboration between academic groups and pharmaceutical sponsors is especially important in a therapeutic class that depends on tightly linked preclinical biology, phase-based drug development, and careful safety monitoring. Myosin inhibitors are not simple symptom agents; they alter the contractile apparatus, so dose selection, patient selection, and physiologic monitoring all carry real weight.
JACC and a small cluster of investigators drove the field’s influence
Publication venue also reflected the specialty’s core interests. Journal of the American College of Cardiology emerged as the leading journal with 16 papers and 937 citations, reinforcing how closely this research is tied to cardiovascular practice. High-impact journals tend to attract studies with direct relevance to clinical decision-making, and myosin inhibitor work fits that pattern because it reaches into obstruction physiology, symptom burden, and disease modification in hypertrophic cardiomyopathy.
At the investigator level, Olivotto I was the most productive author with 40 papers and an h-index of 16. Saberi S received 1,957 citations and emerged as the most cited researcher, while Sehnert AJ combined 27 papers with an h-index of 16, marking strong influence across the network. These names appear repeatedly because the field remains relatively concentrated around a limited number of investigators who have built the earliest mechanistic and clinical platforms. In a young therapeutic area, citation density often reflects who established the conceptual scaffolding first.
Foundational studies continued to anchor later clinical work
Citation mapping showed a clear temporal sequence in which early mechanistic publications, including Green et al in 2016, were repeatedly cited by later clinically oriented studies. That pattern is clinically sensible. Myosin inhibitors act upstream of many downstream manifestations in hypertrophic cardiomyopathy, and the biologic logic has to be established before large-scale therapeutic testing can progress. Early papers helped define the contractile abnormalities the drugs are meant to blunt, while later studies asked whether those biologic effects translate into fewer symptoms, better function, and more individualized treatment strategies.
A 4.2% annual growth rate in artificial intelligence applications also appeared in the keyword and trend analysis. Even in a cardiomyopathy field, this signal is relevant. AI-driven methods can support literature synthesis, phenotype clustering, and perhaps future patient stratification by identifying patterns too complex for manual review alone. As the literature expands, automated mapping may become increasingly useful for sorting mechanistic themes from clinical signals and separating highly cited papers from genuinely practice-changing evidence.
Collaboration gaps remain despite rapid expansion
The network structure exposed a recurring limitation in the field: global collaboration remains uneven. North America and Europe dominate the output, while broader international participation is thinner. For a condition with worldwide clinical burden, that imbalance can narrow the diversity of study populations, limit generalizability, and slow the spread of expertise. A therapy class built around sarcomeric biology should eventually be evaluated across different health systems, patient profiles, and access environments.
This gap is not just an academic issue. Myosin inhibitor use in hypertrophic cardiomyopathy will ultimately depend on real-world tolerability, treatment sequencing, and the practicalities of integrating a targeted drug into routine cardiology care. Publication counts alone do not answer whether patients in community settings mirror trial participants, whether combination regimens offer added value, or how durable benefits hold up outside tightly controlled studies. Those questions become more pressing as the literature matures.
The field has clearly moved from concept to accumulation. What it still lacks is broader geographic participation, richer real-world evidence, and a fuller map of how myosin inhibitors should fit among other targeted strategies for hypertrophic cardiomyopathy.